<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297606</url>
  </required_header>
  <id_info>
    <org_study_id>PM1</org_study_id>
    <nct_id>NCT03297606</nct_id>
  </id_info>
  <brief_title>Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)</brief_title>
  <acronym>CAPTUR</acronym>
  <official_title>Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer drugs which target the effects of abnormal gene changes are called 'targeted
      therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are
      currently available. The purpose of this study is to find out what are the effects on a
      patient and their cancer when they are given a targeted therapy drug that is specific to an
      abnormal gene change in their cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent advances in laboratory technology have enabled the identification of changes in the
      genetic makeup of tumors that might be responsible for their malignant behavior such as
      uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be
      cancer medicines that can specifically act on the tumour's genetic abnormality. Several
      cancer centers and programs have initiated this type of molecular profiling across Canada,
      with the goal to identify 'druggable' changes in tumors to find matching therapy for
      patients. These include initiatives in British Columbia, Ontario and Quebec for adult
      tumours, as well as a pan-Canadian profiling centre for pediatrics. The CAnadian Profiling
      and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of
      commercially available targeted agents in patients who have undergone tumor profiling by one
      of the above mentioned programs, and have 'druggable' changes identified in their cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate defined as the number of patients with complete response or partial response</measure>
    <time_frame>4 years</time_frame>
    <description>over the total number of patients in the given tumour type cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>4 years</time_frame>
    <description>measured by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival confirmed by disease-appropriate objective criteria</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRG, EGFR, ERRB2, ERRB3, ERRB4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGFR1, VEGFR2, VEGFR3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bcr-abl, SRC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALK, ROS1, MET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KIT, PDGFRA, PDGFRB, ABL1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high mutational burden, POLE, POLD1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRCA1, BRCA2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDKN2A, CDK4, CDK6, CCND1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT FLT3, RET, FGFR1, FGFR2, FGFR3, VHL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STKII, TSC1, TSC2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERBB2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRAFV600</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTCH1, SMO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>400mg taken twice daily</description>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100mg administered orally once daily</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab plus Ipilimumab</intervention_name>
    <description>Combination Phase - 1mg/kg nivolumab administered as an intravenous infusion over 60 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 3mg/kg administered intravenously over 90 minutes, followed by the single-agent phase.
Single-Agent Phase - 3mg/kg nivolumab administered as an IV infusion over 60 minutes every 2 weeks.</description>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>40mg once daily</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5mg orally twice daily</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>500mg orally once daily</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>250mg orally twice daily</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days</description>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off</description>
    <arm_group_label>Group 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25mg infused over a 30-60 minute period once a week</description>
    <arm_group_label>Group 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg orally, once daily</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab plus Pertuzumab</intervention_name>
    <description>Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.
Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.</description>
    <arm_group_label>Group 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib plus Cobimetinib</intervention_name>
    <description>Vemurafenib = 960 mg (four 240 mg tablets) orally every 12 hours.
Cobimetinib = 60 mg (three 20 mg tablets) orally once daily for 21 days, followed by 7 days of rest</description>
    <arm_group_label>Group 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>150mg taken orally, once daily</description>
    <arm_group_label>Group 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (screening step - non-drug specific)

          -  Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid
             tumour, multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL),
             for whom there is no standard treatment known to prolong life, or who has refused such
             treatment.

          -  ECOG performance status 0-2.

          -  Patients must have acceptable organ function as defined below. Drug-specific
             eligibility / ineligiblity criteria specified in the appendix for each agent will take
             precedence for this and all inclusion criteria:

               1. Absolute neutrophil count:

                    -  1.5 x 10^9/L for solid tumours;

                    -  1.0 x 10^9/L for hematologic malignancies.

               2. Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma
                  or lymphoma).

               3. Total bilirubin 1.5 x&lt; UNL.

               4. AST (SGOT) and ALT(SGPT) &lt; 2.5 x institutional upper limit of normal (ULN) (or &lt;
                  5 x ULN in patients with known hepatic metastases).

               5. Serum creatinine ≤ 1.5 x ULN or calculated (Cackroft-Gault) or measured
                  creatinine clearance ≥ 50 mL/min/1.73 m2.

          -  Patients must have measurable disease

          -  Results must be available from tumour genomic or protein expression testing. The test
             may have been performed on the primary tumour or a metastatic deposit (including bone
             marrow) in a diagnostic or research laboratory and must reveal a potentially
             'actionable' variant.

          -  Patient consent (Main Study Consent for the screening step) must be appropriately
             obtained in accordance with applicable local and regulatory requirements. Each patient
             must sign a consent form prior to the screening step to document their willingness to
             participate

          -  Patients must be accessible for treatment and follow-up. Patients registered on this
             trial must be treated and followed at the participating centre. This implies there
             must be reasonable geographical limits (for example: 1 ½ hour's driving distance)
             placed on patients being considered for this trial.

          -  Women/men of childbearing potential must have agreed to use a highly effective
             contraceptive method.

        Exclusion Criteria: (screening step - non-drug specific)

          -  Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy,
             related to prior anti-tumour treatment. Patients with ongoing peripheral neuropathy of
             ≥ CTCAE grade 3 will be excluded.

          -  Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic,
             radiation, or hormonal other than for replacement) except for medications that are
             prescribed for supportive care but may potentially have an anti-cancer effect (e.g.
             megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate
             cancer. These medications must have been started ≥ one month prior to enrollment on
             this study. Patients may be on warfarin, low molecular weight heparin or direct factor
             Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility
             criteria.

          -  Patients with known active progressive brain metastases. Patients with previously
             treated brain metastases are eligible, provided that the patient has not experienced a
             seizure or had a clinically significant change in neurological status within one month
             prior to screening. All patients with previously treated brain metastases must be
             stable (clinically and radiologically) for at least one month after completion of
             treatment and either off steroid treatment or only taking physiological doses of
             steroids prior to the screening step.

          -  Patients with clinically significant pre-existing cardiac conditions, including
             uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or
             symptomatic congestive heart failure.

          -  Patients with known left ventricular ejection fraction (LVEF) &lt; 40%.

          -  Patients with stroke (including TIA) or acute myocardial infarction within three
             months prior to the screening step.

          -  Patients with acute gastrointestinal bleeding within one month prior to the screening
             step.

          -  Patients with any other clinically significant medical condition which, in the opinion
             of the treating physician, makes it undesirable for the patient to participate in the
             study or which could jeopardize compliance with study requirements including, but not
             limited to: ongoing or active infection, significant uncontrolled hypertension, or
             severe psychiatric illness/social situations.

          -  Lactating and nursing women

          -  Patients who do not meet drug-specific eligibility requirements for the drug selected
             by the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian Siu</last_name>
    <role>Study Chair</role>
    <affiliation>Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel J Renouf</last_name>
    <role>Study Chair</role>
    <affiliation>BCCA - Vancouver Cancer Centre, Vancouver BC, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Dancey</last_name>
    <phone>613-533-6430</phone>
    <email>jdancey@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel John Renouf</last_name>
      <phone>604 877-6000</phone>
      <phone_ext>672357</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Welch</last_name>
      <phone>519 685-8640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hilton</last_name>
      <phone>613 737-7700</phone>
      <phone_ext>70179</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian Siu</last_name>
      <phone>416 946-2911</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

